1110006G14Rik Inhibitors
Chemical inhibitors of 1110006G14Rik can exert their effects through various signaling pathways by targeting specific kinases that are upstream regulators of this protein's function. LY294002 and Wortmannin, for example, both act by inhibiting phosphoinositide 3-kinases (PI3K), which play a critical role in the PI3K/Akt pathway. The inhibition of PI3K leads to a reduced activation of Akt, a kinase that is pivotal for the phosphorylation of numerous downstream proteins, including 1110006G14Rik. This results in a decrease in 1110006G14Rik activity due to insufficient phosphorylation by Akt. Similarly, PD98059 and U0126 inhibit MEK1/2, which are integral components of the MAPK/ERK pathway. By preventing the activation of MEK1/2, these inhibitors effectively reduce the phosphorylation and activation of proteins that are regulated by the MAPK/ERK pathway, which includes 1110006G14Rik.
On the other hand, SB203580 specifically targets p38 MAPK, inhibiting the activation of proteins in the p38 MAPK signaling pathway, thereby modulating the function of 1110006G14Rik if it is a downstream target. SP600125 operates by inhibiting c-Jun N-terminal kinase (JNK), impeding the phosphorylation of JNK substrates and consequently affecting the function of 1110006G14Rik if it falls within the spectrum of JNK responsive proteins. Rapamycin, by inhibiting mammalian target of rapamycin (mTOR), suppresses the activity of proteins that require mTOR for activation, potentially including 1110006G14Rik. PP2 and Dasatinib are inhibitors of Src family kinases and Abl kinases. The inhibition of these kinases by PP2 and Dasatinib can lead to a reduction in phosphorylation and subsequent activation of their substrates, influencing the functional activity of 1110006G14Rik. Lastly, Gefitinib, Erlotinib, and Lapatinib are all tyrosine kinase inhibitors that target EGFR, with Lapatinib also targeting HER2. By blocking EGFR and HER2, these inhibitors can prevent the activation of proteins that are regulated by EGFR/HER2-mediated signaling, which may include 1110006G14Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is a kinase upstream of Akt signaling. Since Akt can activate a multitude of proteins, including 1110006G14Rik, inhibition of PI3K by LY294002 would prevent the activation of Akt and subsequently inhibit the functional activity of 1110006G14Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that works by irreversibly binding to the PI3K enzyme. By inhibiting PI3K, Wortmannin would block the PI3K/Akt pathway, leading to a decrease in Akt-mediated phosphorylation of downstream proteins, thus functionally inhibiting 1110006G14Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK1/2, which are upstream of the MAPK/ERK pathway. The ERK pathway can lead to phosphorylation and activation of a variety of proteins. Inhibition of this pathway by PD98059 would prevent such activations, thereby inhibiting the function of 1110006G14Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which prevents the activation of the MAPK/ERK pathway. This inhibition would result in the functional suppression of downstream proteins potentially activated by ERK, like 1110006G14Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAPK. By inhibiting p38 MAPK, SB203580 would prevent the activation of downstream proteins that depend on p38 signaling, thereby inhibiting the function of 1110006G14Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 would prevent the phosphorylation and activation of proteins that are substrates for JNK, thus functionally inhibiting 1110006G14Rik if it is a JNK substrate. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in the mTOR signaling pathway. Inhibition of mTOR by Rapamycin would lead to the suppression of downstream proteins that require mTOR for their activation, resulting in the functional inhibition of 1110006G14Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 would prevent the phosphorylation of downstream proteins that are activated by Src kinases, which would inhibit the function of 1110006G14Rik if it were a Src kinase substrate. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib broadly inhibits Src family kinases and Abl kinases. The inhibition of these kinases by Dasatinib would lead to decreased phosphorylation and activation of their substrates, functionally inhibiting 1110006G14Rik if it is reliant on Src or Abl kinase activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibiting EGFR by Gefitinib would suppress the downstream signaling pathways that depend on EGFR-mediated activations, thus functionally inhibiting 1110006G14Rik if it is part of the EGFR signaling pathway. | ||||||